FR05C0047I2 - - Google Patents

Info

Publication number
FR05C0047I2
FR05C0047I2 FR05C0047C FR05C0047C FR05C0047I2 FR 05C0047 I2 FR05C0047 I2 FR 05C0047I2 FR 05C0047 C FR05C0047 C FR 05C0047C FR 05C0047 C FR05C0047 C FR 05C0047C FR 05C0047 I2 FR05C0047 I2 FR 05C0047I2
Authority
FR
France
Prior art keywords
ones
pyran
retrovirus
hydroxy
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0047C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of FR05C0047I1 publication Critical patent/FR05C0047I1/fr
Application granted granted Critical
Publication of FR05C0047I2 publication Critical patent/FR05C0047I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR05C0047C 1994-05-06 2005-12-22 Active FR05C0047I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23881794A 1994-05-06 1994-05-06
US34936194A 1994-12-02 1994-12-02
PCT/US1995/005219 WO1995030670A2 (en) 1994-05-06 1995-05-04 Pyranone compounds useful to treat retroviral infections

Publications (2)

Publication Number Publication Date
FR05C0047I1 FR05C0047I1 (enExample) 2006-03-10
FR05C0047I2 true FR05C0047I2 (enExample) 2007-10-19

Family

ID=26931995

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0047C Active FR05C0047I2 (enExample) 1994-05-06 2005-12-22

Country Status (32)

Country Link
US (2) US5852195A (enExample)
EP (1) EP0758327B1 (enExample)
JP (1) JP3883206B2 (enExample)
KR (1) KR100445929B1 (enExample)
CN (2) CN1154642C (enExample)
AT (1) ATE236894T1 (enExample)
AU (2) AU701965B2 (enExample)
BR (1) BR9507615A (enExample)
CA (2) CA2560489C (enExample)
CO (1) CO4810313A1 (enExample)
CZ (1) CZ296515B6 (enExample)
DE (2) DE69530294T2 (enExample)
DK (1) DK0758327T3 (enExample)
ES (1) ES2192201T3 (enExample)
FI (1) FI117387B (enExample)
FR (1) FR05C0047I2 (enExample)
HU (1) HU228057B1 (enExample)
IL (3) IL129871A (enExample)
LU (1) LU91220I2 (enExample)
MX (1) MX9605391A (enExample)
MY (2) MY149862A (enExample)
NL (1) NL300216I2 (enExample)
NO (2) NO315799B1 (enExample)
NZ (1) NZ285510A (enExample)
PE (1) PE23196A1 (enExample)
PL (1) PL190540B1 (enExample)
PT (1) PT758327E (enExample)
RU (1) RU2139284C1 (enExample)
SI (1) SI0758327T1 (enExample)
SK (1) SK284407B6 (enExample)
TW (1) TW504507B (enExample)
WO (1) WO1995030670A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
AU3498397A (en) * 1996-07-03 1998-01-21 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
CN1112927C (zh) * 1997-07-29 2003-07-02 法玛西雅厄普约翰美国公司 自体乳化剂形式的酸性亲脂性化合物的药物组合物
KR100509130B1 (ko) 1997-07-29 2005-08-18 파마시아 앤드 업존 캄파니 엘엘씨 친지성 화합물의 자가유화 제제
SK284511B6 (sk) * 1997-07-29 2005-05-05 Pharmacia & Upjohn Company Samoemulgujúce formulácie pre lipofilné zlúčeniny
CZ298847B6 (cs) * 1997-09-11 2008-02-27 Pharmacia & Upjohn Company Zpusob výroby proteázového inhibitoru
PT1161427E (pt) 1999-03-18 2003-03-31 Upjohn Co Processo melhorado para hidrogenacao assimetrica
US6956048B2 (en) * 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
BR0011864A (pt) 2000-01-19 2004-07-20 Abbott Lab Formulações farmacêuticas
FI113942B (fi) * 2000-08-18 2004-07-15 Control Ox Oy Kasviperäisten fenolisten yhdisteiden käyttö valmistettaessa klamydiainfektion hoidossa ja ennaltaehkäisyssä käyttökelpoista farmaseuttista valmistetta, terveyteen myönteisesti vaikuttavaa ravintoainekoostumusta tai koostumusta lisättäväksi tällaisiin elintarvikkeisiin
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
BR0307944A (pt) * 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
AU2003215826A1 (en) * 2002-04-01 2003-10-13 Pfizer Inc. Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
RU2234535C2 (ru) * 2002-10-03 2004-08-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Субстрат для определения активности интегразы вируса иммунодефицита человека
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
IL161586A (en) * 2004-04-22 2015-02-26 Rafael Advanced Defense Sys Irreplaceable energetic material and reactive shielding that uses it
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
EP1814547A1 (en) * 2004-11-16 2007-08-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
JP2008520701A (ja) * 2004-11-19 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びレバーセットの同時投与を介したｈｉｖ感染症の治療方法
WO2006055660A2 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006060159A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
WO2006060177A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
EP1819335A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US20090062346A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched tipranavir
CA2700132A1 (en) * 2007-09-25 2009-04-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
KR101076680B1 (ko) * 2007-11-01 2011-10-26 한미홀딩스 주식회사 (6ｒ)-3-헥실-4-히드록시-6-운데실-5,6-다이히드로피란-2-온의 제조방법 및 이에 사용되는 중간체
EP2262498A2 (en) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
GEAP202213376A (en) 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
WO2012033846A1 (en) 2010-09-09 2012-03-15 Rutgers, The State University Of New Jersey Arylpropionyl-triketone antibacterial agents
WO2012033815A1 (en) * 2010-09-09 2012-03-15 Rutgers, The State University Of New Jersey Arylpropionyl-alpha-pyrone antibacterial agents
US9133155B2 (en) 2010-09-17 2015-09-15 Rutgers, The State University Of New Jersey Antibacterial agents: high-potency myxopyronin derivatives
EP2632895B1 (en) 2010-10-28 2018-10-03 Merck Canada Inc. Hiv protease inhibitors
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
US9517994B2 (en) 2012-01-05 2016-12-13 Rutgers, The State University Of New Jersey Antibacterial agents: phloroglucinol derivatives
RU2015113091A (ru) * 2012-09-11 2016-11-10 Мерк Шарп И Доум Корп. Ингибиторы протеазы вич
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
EP3113780B1 (en) 2014-03-06 2019-08-14 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015138220A1 (en) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017100645A2 (en) 2015-12-10 2017-06-15 Rutgers, The State University Of New Jersey Inhibitors of bacterial rna polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols
WO2017156458A1 (en) * 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
US11993590B2 (en) * 2016-12-04 2024-05-28 712 North Inc. Pyranone compounds useful to modulate OMA1 protease
US11685723B2 (en) 2018-02-13 2023-06-27 Rutgers, The State University Of New Jersey Antibacterial agents: O-alkyl-deuterated pyronins
US12209082B2 (en) 2018-02-13 2025-01-28 Rutgers, The State University Of New Jersey Antibacterial agents: soluble salts and aqueous formulations of pyronins
WO2019173507A1 (en) 2018-03-06 2019-09-12 Rutgers, The State University Of New Jersey Antibacterial agents : arylalkylcarboxamido phloroglucinols
CN110551090B (zh) * 2019-10-21 2021-06-18 扬州工业职业技术学院 一种超声波提取中药狗脊中抗肿瘤活性成分的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2026500342A (ja) * 2022-12-16 2026-01-06 テンヴァイ セラピューティクス， インコーポレイテッド 化合物、組成物、及び方法
CN116730993B (zh) * 2023-04-25 2026-01-23 浙江科技学院 一种替拉那韦中间体及替拉那韦的制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB193507A (en) 1921-11-25 1923-02-26 English Electric Co Ltd Improvements in and connected with hydraulic impulse turbines
NL80964C (enExample) * 1952-03-08
BE519956A (enExample) * 1952-05-16
US2723277A (en) * 1952-08-26 1955-11-08 Hoffmann La Roche Malonic acid derivatives and process for the manufacture thereof
US2872457A (en) * 1956-04-19 1959-02-03 Wisconsin Alumni Res Found Process for the preparation of 4-hydroxycoumarin derivatives
GB836740A (en) * 1956-04-25 1960-06-09 Bayer Ag Coumarin derivatives and their production
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1463767A (fr) * 1963-04-03 1966-07-22 Clin Byla Ets Dérivés de la coumarine et leur préparation
BE674997A (enExample) * 1965-01-13 1966-07-12
FR1559595A (enExample) * 1966-12-13 1969-03-14
US3489774A (en) * 1967-04-24 1970-01-13 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno) propionyl)-coumarin products
US3493586A (en) * 1969-01-23 1970-02-03 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno)-propionyl)pyrone products
JPS4823942B1 (enExample) * 1969-02-14 1973-07-17
US3764693A (en) * 1969-11-21 1973-10-09 Lipha A rodenticidal compositions containing 4-hydroxy coumarins
US3835161A (en) * 1972-10-24 1974-09-10 Realisations Scient S E Res C 3-substituted-4-hydroxy-coumarins
US3931235A (en) * 1972-12-18 1976-01-06 The Dow Chemical Company Process for preparing sulfur-containing hydroxy pyrones
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
IL60751A (en) * 1979-08-17 1985-04-30 Merck & Co Inc 6-(2'-((substituted phenyl)ethyl and-ethenyl)-4-hydroxy-tetrahydro-2h-pyran-2-one derivatives,their preparation and pharmaceutical compositions containing them
CA1171424A (en) * 1981-06-17 1984-07-24 Alvin K. Willard ( )-(4r, 6s) - (e)-6-[2-(4'fluro-3,3', 5-trimethyl- [l,l'-biphenyl]-2-yl)ethenyl]-3,4,5,6- tetrahydro-4-hydroxy-2h-pyran-2-one
JPS634652A (ja) * 1986-06-25 1988-01-09 Hitachi Ltd 半導体装置
WO1988004652A1 (fr) 1986-12-17 1988-06-30 Nippon Soda Co., Ltd. Composes heterocycliques possedant un squelette triketo
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
WO1989007939A2 (en) * 1988-03-01 1989-09-08 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
JPH05503073A (ja) * 1989-09-26 1993-05-27 オクタマー，インコーポレイテッド ウイルス性疾患の治療に有用な６―アミノ―１，２―ベンゾピロン
JPH05501879A (ja) * 1989-10-27 1993-04-08 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルスを処理する方法およびそれに有用な化合物
JPH03227923A (ja) 1990-01-30 1991-10-08 Sawai Seiyaku Kk ひと免疫不全ウイルス疾患処置剤
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
DE69128481T2 (de) * 1990-09-07 1998-04-09 Schering Corp Antivirale und antihypertensive verbindungen
WO1992004326A1 (en) * 1990-09-07 1992-03-19 Schering Corporation Antiviral compounds
CA2091173A1 (en) * 1990-09-07 1992-03-08 Adriano Afonso Antiviral compounds and antihypertensive compounds
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
EP0578745A1 (en) * 1991-04-04 1994-01-19 The Upjohn Company Phosphorus containing compounds as inhibitors of retroviruses
HU221816B1 (hu) * 1991-10-11 2003-01-28 Bristol-Myers Squibb Pharma Company Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
EP0609211A4 (en) * 1991-10-22 1995-02-01 Octamer Inc NITROUS AROMATIC COMPOUNDS THAT BIND ADENOSINE DIPHOSPHORIBOSIS POLYMERASE AS EFFECTIVE ANTI-TUMOR AND ANTI-RETROVIRUS AGENTS.
DE4308451A1 (de) * 1992-09-10 1994-04-14 Bayer Ag 3-Aryl-pyron-Derivate
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections

Also Published As

Publication number Publication date
CN1539825A (zh) 2004-10-27
KR100445929B1 (ko) 2005-09-30
PT758327E (pt) 2003-08-29
PE23196A1 (es) 1996-06-07
HUT77601A (hu) 1998-06-29
SK138496A3 (en) 1997-06-04
RU2139284C1 (ru) 1999-10-10
IL129871A0 (en) 2000-02-29
IL129871A (en) 2003-11-23
AU2462695A (en) 1995-11-29
JPH09512821A (ja) 1997-12-22
WO1995030670A3 (en) 1996-04-25
AU718117B2 (en) 2000-04-06
HU228057B1 (en) 2012-09-28
PL317061A1 (en) 1997-03-03
CZ296515B6 (cs) 2006-04-12
NL300216I1 (nl) 2006-04-03
US5852195A (en) 1998-12-22
DE69530294T2 (de) 2003-12-24
CA2560489A1 (en) 1995-11-16
NO2006003I1 (no) 2006-03-13
AU701965B2 (en) 1999-02-11
CA2560489C (en) 2010-01-12
NL300216I2 (nl) 2006-06-01
US6169181B1 (en) 2001-01-02
CN1329378C (zh) 2007-08-01
NZ285510A (en) 1998-03-25
MY149862A (en) 2013-10-31
ATE236894T1 (de) 2003-04-15
DE122006000014I2 (de) 2007-03-29
SI0758327T1 (en) 2003-08-31
CO4810313A1 (es) 1999-06-30
KR970702858A (ko) 1997-06-10
ES2192201T3 (es) 2003-10-01
LU91220I2 (fr) 2006-04-10
CZ317296A3 (en) 1997-04-16
CN1150424A (zh) 1997-05-21
PL190540B1 (pl) 2005-12-30
HK1066796A1 (zh) 2005-04-01
EP0758327A1 (en) 1997-02-19
EP0758327B1 (en) 2003-04-09
HU9603074D0 (en) 1997-01-28
NO964676D0 (no) 1996-11-05
CA2187523C (en) 2006-11-21
MY127701A (en) 2006-12-29
NO964676L (no) 1997-01-06
TW504507B (en) 2002-10-01
NO315799B1 (no) 2003-10-27
FR05C0047I1 (enExample) 2006-03-10
WO1995030670A2 (en) 1995-11-16
SK284407B6 (sk) 2005-03-04
DK0758327T3 (da) 2003-07-28
FI117387B (fi) 2006-09-29
DE122006000014I1 (de) 2006-11-16
FI964441A0 (fi) 1996-11-05
NO2006003I2 (no) 2008-10-20
DE69530294D1 (de) 2003-05-15
FI964441L (fi) 1996-11-05
AU2368699A (en) 1999-06-03
JP3883206B2 (ja) 2007-02-21
MX9605391A (es) 1997-12-31
BR9507615A (pt) 1997-09-09
CA2187523A1 (en) 1995-11-16
CN1154642C (zh) 2004-06-23
IL113567A (en) 2003-05-29
HK1084667A1 (en) 2006-08-04

Similar Documents

Publication Publication Date Title
FR05C0047I2 (enExample)
MY119031A (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
NO953070D0 (no) 4-hydroksy-benzopyran-2-oner og 4-hydroksysykloalkyl[BÅpyran-2-oner anvendbare for behandling av retrovirusinfeksjoner
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
TR199700470A2 (xx) Sildenafilin haz�rlanmas� i�in proses.
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
NZ325235A (en) New phenylamidine derivatives, a process for preparing the same and their use as medicaments
AU8460791A (en) Compound, preparation and use
GB2055366B (en) 2-phenylimino-5-(2'-carboxyphenyl)-1,3,4-thiadiazol-4-ine derivatives useful as plant-growth regulating agents
AU4188700A (en) Pseudomycin natural products
ES2151820A1 (es) Herbicidas a base de derivados de 1,3-oxazin-4-ona, composiciones que los contienen y procedimiento para su preparacion.